West Pharmaceutical Services Inc WST
We take great care to ensure that the data presented and summarized in this overview for WEST PHARMACEUTICAL SERVICES INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding WST
View all-
Vanguard Group Inc Valley Forge, PA8.99MShares$2.09 Billion0.05% of portfolio
-
Black Rock Inc. New York, NY7.58MShares$1.76 Billion0.06% of portfolio
-
State Street Corp Boston, MA3.25MShares$754 Million0.04% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.11MShares$723 Million1.63% of portfolio
-
Alliancebernstein L.P. New York, NY2.59MShares$602 Million0.3% of portfolio
-
Brown Advisory Inc2.55MShares$593 Million1.11% of portfolio
-
Franklin Resources Inc San Mateo, CA1.78MShares$414 Million0.17% of portfolio
-
Geode Capital Management, LLC Boston, MA1.78MShares$413 Million0.05% of portfolio
-
Apg Asset Management N.V. Amsterdam, P71.44MShares$334 Million1.3% of portfolio
-
Morgan Stanley New York, NY1.03MShares$240 Million0.02% of portfolio
Latest Institutional Activity in WST
Top Purchases
Top Sells
About WST
West Pharmaceutical Services, Inc. designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, washing, and vision inspection and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including Crystal Zenith, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as a range of integrated solutions, including analytical lab services, pre-approval primary packaging support and engineering development, regulatory expertise, and after-sales technical support. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. It serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was incorporated in 1923 and is headquartered in Exton, Pennsylvania.
Insider Transactions at WST
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Feb 18
2025
|
Bernard Birkett Sr VP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
272
-1.78%
|
$57,392
$211.0 P/Share
|
Feb 18
2025
|
Bernard Birkett Sr VP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
903
+5.42%
|
$190,533
$211.0 P/Share
|
Feb 18
2025
|
Cindy Reiss Clark Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-1.62%
|
$17,513
$211.0 P/Share
|
Feb 18
2025
|
Cindy Reiss Clark Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+4.58%
|
$51,906
$211.0 P/Share
|
Feb 18
2025
|
Chad Winters VP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
27
-1.94%
|
$5,697
$211.0 P/Share
|
Feb 18
2025
|
Chad Winters VP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
82
+5.57%
|
$17,302
$211.0 P/Share
|
Feb 18
2025
|
Annette F Favorite Sr. VP & Chief HR Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
83
-1.22%
|
$17,513
$211.0 P/Share
|
Feb 18
2025
|
Annette F Favorite Sr. VP & Chief HR Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+3.48%
|
$51,906
$211.0 P/Share
|
Feb 18
2025
|
Kimberly Banks Mac Kay SVP, GC & Corporate Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
92
-5.74%
|
$19,412
$211.0 P/Share
|
Feb 18
2025
|
Kimberly Banks Mac Kay SVP, GC & Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
246
+13.3%
|
$51,906
$211.0 P/Share
|
Feb 18
2025
|
Eric Mark Green President, CEO and Board Chair |
SELL
Payment of exercise price or tax liability
|
Direct |
700
-0.41%
|
$147,700
$211.0 P/Share
|
Feb 18
2025
|
Eric Mark Green President, CEO and Board Chair |
BUY
Exercise of conversion of derivative security
|
Direct |
2,460
+1.42%
|
$519,060
$211.0 P/Share
|
Feb 18
2025
|
Charles Witherspoon VP & Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
23
-1.75%
|
$4,853
$211.0 P/Share
|
Feb 18
2025
|
Charles Witherspoon VP & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
65
+4.7%
|
$13,715
$211.0 P/Share
|
Dec 16
2024
|
Janet Brutschea Haugen Director |
BUY
Grant, award, or other acquisition
|
Direct |
424
+50.0%
|
-
|
Oct 29
2024
|
Charles Witherspoon VP & Treasurer |
SELL
Open market or private sale
|
Direct |
703
-19.83%
|
$217,930
$310.4 P/Share
|
Oct 29
2024
|
Charles Witherspoon VP & Treasurer |
BUY
Exercise of conversion of derivative security
|
Direct |
478
+19.64%
|
$82,694
$173.22 P/Share
|
Oct 29
2024
|
Silji Abraham SVP, Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
180
-5.43%
|
$57,240
$318.41 P/Share
|
Oct 29
2024
|
Silji Abraham SVP, Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
458
+12.13%
|
-
|
Aug 19
2024
|
Charles Witherspoon VP & Treasurer |
SELL
Open market or private sale
|
Direct |
1,029
-23.19%
|
$308,700
$300.0 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 6.06K shares |
---|---|
Exercise of conversion of derivative security | 118K shares |
Payment of exercise price or tax liability | 1.46K shares |
---|---|
Open market or private sale | 102K shares |